Skip to main content

20 Result(s)

within D. Maraninchi Remove this filter Medicine & Public Health Remove this filter Cell Biology Remove this filter Medicine/Public Health, general Remove this filter Public Health Remove this filter

and

  1. No Access

    Article

    Randomized study of early hospital discharge following autologous blood SCT: medical outcomes and hospital costs

    We report the first randomized study comparing early hospital discharge with standard hospital-based follow-up after high-dose chemotherapy (HDCT) and PBSCT. Patients aged 18–65 years, with an indication of PB...

    C Faucher, A G Le Corroller Soriano, B Esterni, N Vey… in Bone Marrow Transplantation (2012)

  2. No Access

    Article

    A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma

    The potential benefit of rituximab as adjuvant to high-dose therapy (HDT) has been investigated in patients under 60 years with poor-risk (age-adjusted international prognostic index at 2–3) CD20+ diffuse larg...

    D Coso, C Sebban, O Boulat, P Biron, J Rey, T Aurran… in Bone Marrow Transplantation (2006)

  3. No Access

    Article

    Early administration of recombinant erythropoietin improves hemoglobin recovery after reduced intensity conditioned allogeneic stem cell transplantation

    The use of recombinant human erythropoietin (rHuEPO) has been controversial after myeloablative allogeneic Stem cell transplantation (allo-SCT). Reduced intensity conditioning regimens (RIC) offer a novel appr...

    V Ivanov, C Faucher, M Mohty, K Bilger, P Ladaique, D Sainty… in Bone Marrow Transplantation (2005)

  4. No Access

    Article

    Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation

    In all, 41 multiple myeloma (MM) patients received an antithymocyte globulin (ATG), fludarabine, and busulfan-based reduced intensity conditioning (RIC) for allogeneic stem cell transplantation (allo-SCT) from...

    M Mohty, J M Boiron, G Damaj, A S Michallet, J O Bay… in Bone Marrow Transplantation (2004)

  5. No Access

    Article

    Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment

    The prognosis of inflammatory breast cancer (IBC) is poor. We evaluated clinical and biopathological characteristics that could affect survival in 74 women with nonmetastatic IBC consecutively treated in our i...

    F Bertucci, C Tarpin, E Charafe-Jauffret, V-J Bardou… in Bone Marrow Transplantation (2004)

  6. No Access

    Article

    Autologous stem cell transplantation for acute myelogenous leukemia in first complete remission: a 6-year follow-up study of 101 patients from a single institution

    The objective of the study was to assess the long-term outcome and impact of stem cell source in patients with acute myelogenous leukemia (AML) who received ASCT in first complete remission (CR). A total of 10...

    N Vey, R Bouabdallah, A Stoppa, C Faucher, M Lafage… in Bone Marrow Transplantation (2004)

  7. No Access

    Article

    Occult tumor cell contamination in patients with stage II/III breast cancer receiving sequential high-dose chemotherapy

    The purpose of this study was to evaluate the presence of micrometastatic cells in the apheresis products from patients with breast cancer, and also to determine if repeated infusion of contaminated products h...

    F Viret, C Chabannon, D Sainty, D Genre, A Gonçalves… in Bone Marrow Transplantation (2003)

  8. No Access

    Article

    Intensive sequential dose dense chemotherapy with stem cell support as first-line treatment in advanced ovarian carcinoma: a phase II study

    From August 1995 to December 1997, 15 patients with stage III–IV ovarian cancer were treated with outpatient intensive chemotherapy with G-CSF and stem cell support. The first cycle consisted of cyclophophamid...

    F Viret, F Bertucci, D Genre, G Gravis, C Chabannon, M Conte… in Bone Marrow Transplantation (2002)

  9. No Access

    Article

    Modulations of dose intensity of doxorubicin and cyclophosphamide in association with G-CSF and peripheral blood stem cells in adjuvant chemotherapy for breast cancer: comparative evaluation of completion and safety of three intensive regimens

    The aim of this study was to evaluate and to compare in terms of toxicity the modulations of dose intensity of cyclophosphamide and doxorubicin in adjuvant chemotherapy for high-risk breast cancer. Four cycles...

    D Genre, P Viens, F Bertucci, C Chabannon, G Gravis… in Bone Marrow Transplantation (2002)

  10. No Access

    Article

    Overexpression of erb B2 remains a major risk factor in non-metastatic breast cancers treated with high-dose alkylating agents and autologous stem cell transplantation

    The importance of dose intensity has been strongly emphasized in high-risk breast cancer. Overexpression of erb B2 is clearly correlated with an overall poor prognosis which could be limited in patients receiv...

    AC Braud, MP Mathoulin Portier, VJ Bardou, F Bertucci… in Bone Marrow Transplantation (2002)

  11. No Access

    Article

    Large granular lymphocytes (LGL) following non-myeloablative allogeneic bone marrow transplantation: a case report

    We report here the first case of large granular lymphocytes (LGL) expansion following non-myeloablative allo-BMT for chronic myeloid leukemia. We characterized the morphologic, phenotypic and functional featur...

    M Mohty, C Faucher, B Gaugler, N Vey, D Sainty, C Arnoulet… in Bone Marrow Transplantation (2001)

  12. No Access

    Article

    High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation

    New approaches using nonmyeloablative-conditioning regimens have been developed to cause minimal procedure-related toxicity. Such novel therapeutic options are being explored with good preliminary results conc...

    M Mohty, C Faucher, N Vey, AM Stoppa, F Viret, I Chabbert… in Bone Marrow Transplantation (2000)

  13. No Access

    Article

    High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results

    The importance of dose intensity has been suggested in ovarian carcinoma. We retrospectively evaluated the long-term results of melphalan-based high-dose chemotherapy (HDC) with hematopoietic rescue in a unice...

    F Bertucci, P Viens, JR Delpero, VJ Bardou, C Faucher… in Bone Marrow Transplantation (2000)

  14. No Access

    Article

    Role of high-dose therapy and initial response in survival of poor-risk patients with aggressive non-Hodgkin's lymphoma: a retrospective series on 126 patients from a single center

    It is now established that a subgroup of non-Hodgkin's lymphoma (NHL) patients probably benefit from high-dose therapy (HDT). We therefore retrospectively analyzed survival of 126 consecutive patients with lar...

    R Bouabdallah, D Coso, R Costello, VJ Bardou, D Blaise… in Bone Marrow Transplantation (2000)

  15. No Access

    Article

    Transplantation of allogeneic CD34+ blood cells in leukemia or lymphoma patients at high risk of GVHD

    F Viret, C Chabannon, T Aurran-Schleinitz, D Reviron… in Bone Marrow Transplantation (1999)

  16. No Access

    Article

    Mobilisation of healthy donors with lenograstim and transplantation of HLA-genoidentical blood progenitors in 54 patients with hematological malignancies: a pilot study

    Blood cell transplantation (BCT) is now common practice in the autologous setting. We performed a pilot study of allogeneic BCT, collected after the priming of an HLA-identical sibling with a glycosylated rhu-...

    D Blaise, E Jourdan, M Michallet, JP Jouet, JM Boiron… in Bone Marrow Transplantation (1998)

  17. No Access

    Article

    High-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer: pathologic response and outcome

    Inflammatory breast cancer still has a poor prognosis despite improvements related to the introduction of neoadjuvant chemotherapy. The purpose of this study was to evaluate pathologic response rate and outcom...

    P Viens, F Penault-Llorca, J Jacquemier, G Gravis, D Cowen… in Bone Marrow Transplantation (1998)

  18. No Access

    Article

    High-dose sequential chemotherapy with stem cell support for non-metastatic breast cancer

    The importance of dose-intensity has been suggested in breast cancer. The aim of this study was to evaluate the feasability of a high-dose intensity doxorubicin-cyclophosphamide regimen with supporting G-CSF a...

    P Viens, G Gravis, D Genre, F Bertucci, D Cowen, J Camerlo… in Bone Marrow Transplantation (1997)

  19. No Access

    Article

    Early and fatal immune haemolysis after so-called ‘minor’ ABO-incompatible peripheral blood stem cell allotransplantation

    A 38-year-old man, blood group A+, was allotransplanted for multiple myeloma from his fully matched sister, blood group O+. Anti-A antibodies IgG and IgM titres of the donor were low. Allogeneic peripheral blo...

    S Oziel-Taieb, C Faucher-Barbey, C Chabannon, P Ladaique… in Bone Marrow Transplantation (1997)

  20. No Access

    Article

    Early allogeneic transplantation favorably influences the outcome of adult patients suffering from acute myeloid leukemia

    Allogeneic BMT for patients with acute myeloid leukemia (AML) is presently a reference therapy. The indications for this therapy mainly rely upon prognostic factors, and their importance is constantly reassess...

    E Jourdan, D Maraninchi, J Reiffers, E Gluckman, B Rio… in Bone Marrow Transplantation (1997)